Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences

Navidea invited to present atherosclerosis and rheumatoid diagnostic imaging data at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging

Navidea selected by the National Institute of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases to present Rheumatoid Arthritis program to investors at the 2017 BIO International Convention

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) (“Navidea”) (“the Company”), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has been invited to present data at two major upcoming conferences.

Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Navidea has been invited to present its Tc99m-tilmanocept receptor-specific diagnosis data for aortic plaques (Nav/MGH), and for rheumatoid arthritis (Nav3-21/23), at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a meeting of leading molecular imaging and nuclear medicine experts representing the world’s top medical and academic institutions and centers.

Event:

        
        
        
        
        
        
          Annual Meeting of the Society of Nuclear Medicine and Molecular 
          Imaging
        
      
      
        
          

Date:

        
        
        
        
        
        
          June 10-14, 2017
        
      
      
        
          

Time:

        
        
        
        
        
        
          June 12, 4:45 - 6:15 PM – Rm 708/710 (Cardio)
        
      
      
        
        
        
        
        
        
        
          June 12, 4:45 - 6:15 PM – Rm 603 (Rheumatoid)
        
      
      
        
          

Location:

        
        
        
        
        
        
          Colorado Convention Center, 700 14th Street, Denver, CO 
          80202
        
      
      
        
        
        
        
        
        
        
           
        
      
    
    

2017 BIO International Convention

Navidea has been selected by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a component of the National Institute of Health (NIH) to present its Rheumatoid Arthritis (RA) program to investors at the 2017 BIO International Convention (BIO 2017). Navidea was selected from more than 1,000 recipients of NIH/NIAMS SBIR grants to present clinical results and their commercial strategy in regards to the development of tilmanocept (Tc99m-Tilmanocept), for the diagnostic imaging of RA.

Event:

        
        
        
        
        
        
          2017 Bio International Convention
        
      
      
        
          

Date:

        
        
        
        
        
        
          June 19-22, 2017
        
      
      
        
          

Time:

        
        
        
        
        
        
          TBD
        
      
      
        
          

Location:

        
        
        
        
        
        
          San Diego Convention Center, 111 W. Harbor Drive, San Diego, CA 92101
        
      
      
        
        
        
        
        
        
        
           
        
      
    
    

About

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including ManoceptTM and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc99m-tilmanocept) injection was the first commercial product of the ManoceptTM platform, was approved by the FDA in March 2013 and in Europe in November 2014. LS North American rights were sold to Cardinal Health for an upfront payment and future contingent payments and licensed in Europe to Norgine. The development activities of the ManoceptTM immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006941/en/

Navidea BiopharmaceuticalsJed Latkin (investors & media)Interim COO & [e-mail] AdvisorsTirth Patel (investors)[e-mail]